Augustin References Abdelsalam A, Del Priore L, Zarbin MA. 1999. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression. Surv Ophthalmol, 44:1-29. Augustin AJ, D’Amico DJ, Mieler WF, et al. 2005. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol, 243:9-12. Augustin AJ, Schmidt-Erfurth U. 2006. Verteporfin therapy combined w i t h i n t r a v i t r e a l t r i a m c i n o l o n e i n a l t y p e s o f c h o r o i d a l neovascularization due to age related macular degeneration. Ophthalmology, 11:14-22. BenEzra D, Griffin BW, Maftzir G, et al. 1997. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci, 58:1954-62. Blei F, Wilson EL, Mignatti P, et al. 1993. Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol, 155:568-78. Christen WG, Glynn RJ, Manson JE, et al. 1996. A prospective study of cigarette smoking and age-related macular degeneration in men. JAMA, 276:1147-51. Clark AF, Penn JS. 2003. eLetter to the Editor: PAI-1 and ocular angiogenesis [online]. Accessed on 12 August 2005. URL: http:// www.iovs.org/cgi/eletters/44/6/2791. Clark AF, Yorio T. 2003. Ophthalmic drug discovery. Nat Rev Drug Discov, 2:448-59. Clark AF, Bingaman DP, Kapin MA. 2000. Ocular angiostatic agents. Exp Opin Ther Patents, 10:427-448. Clark AF, Mellon J, Li XY, et al. 1999. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci, 40:2158-62. Clark AF. 1997. AL-3789: A novel ophthalmic angiostatic steroid. Exp Opin Invest Drugs, 6:1867-77. Crum R, Szabo S, Folkman J. 1985. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science, 230:1375-8. D’Amico DJ, Goldberg MF, Hudson H, et al. 2003. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD); Interim (month 6) analysis of clinical safety and efficacy. Retina 23:14-23. DeFaller JM, Clark AF. 2000. A new pharmacological treatment for angiogenesis. In: Taylor HR (ed). Pterygium. The Hague, Netherlands: Kugler Pub, p 159-81. Gragoudas ES, Adamis AP, Cunningham ET Jr; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. 2004. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 351:2805-16. Hamm WT Jr., Mueller HA, Sliney DH. 1976. Retinal sensitivity to damage from short wavelength light. Nature, 260:153. Kijlstra A, La Heij E, Hendrikse F. 2005. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul Immunol Inflamm, 13:3-11. Klein R, Klein BE, Linton KL. 1992. Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology, 99:933- 43. Liu C, Gu X, Wang W-H, et al. 2005. Local delivery of anecortave acetate inhibits the expression of retinal IGF-1/IGF-1 receptor in the rat OIR model [abstract]. Invest Ophthalmol Vis Sci, ARVO 4135. McNatt LG, Weimer L, Yanni J, et al. 1999. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther, 15:413-23. Newsome DA, Swartz M, Leone NC, et al. 1998. Oral zinc in macular degeneration. Arch Ophthalmol, 6:192-8. Penn JS, Rajaratnam V, Collier RJ, et al. 2001. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci, 42:283-90. Regillo CD, D’Amico D, Mieler W, et al. 2005. Safety outcomes of clinical studies for anecortave acetate in patients with exudative age-related macular degeneration [abstract]. Invest Ophthalmol Vis Sci, ARVO 1373. Seddon JM, Ajani UA, Sperduto RD, et al. 1994. Dietary carotenoids, v i t a m i n s A , C , a n d E , a n d a d v a n c e d a g e - r e l a t e d m a c u l a r degeneration. Eye Disease Case-Control Study Group. JAMA, 272:1413-20. Seddon JM, Rosner B, Sperduto RD, et al. 2001. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol, 119:1191-9. Seddon JM, Willett WC, Speizer FE, et al. 1996. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA, 276:1141-6. Slakter JS, Bochow T, D´Amico DJ, et al. 2006. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology, 113:3-13. Slakter JS, Jerdan J, Kane FE, et al. 2005. Baseline characteristics of a Phase 3 clinical study of anecortave acetate 15 mg in patients with exudative age-related macular degeneration (AMD) [abstract]. Invest Ophthalmol Vis Sci, ARVO 1374. Swann PG, Lovie-Kitchin JE. 1990. Age-related maculopathy; I. A review of its morphology and effects on visual function. Ophthalmic Physiol Opt, 10:149-58. Taylor HR, Munoz B, West S, et al. 1990. Visible light and risk of age- related macular degeneration. Trans Am Ophthalmol Soc, 88:173-80. Vingerling JR, Hofman A, Grobbee DE, et al. 1996. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol, 114:1193-6. Vingerling JR, Klaver CC, Hofman A, et al. 1995. Epidemiology of age- related maculopathy. Epidemiol Rev, 17:347-60. Yang R, McCollum GW, Bingaman DP, et al. 2005. The effect of anecortave acetate on VEGF message and protein levels in hypoxic Müller cells and in rat OIR [abstract]. Invest Ophthalmol Vis Sci, ARVO 4177. 246 Clinical Inter ventions in Aging 2006:1(3)